

SHORT-ACTING OPIOID ANALGESICS PRIOR AUTHORIZATION FORM



Keystone First

PERFORMRxSM
Next Generation Pharmacy Benefits

(form effective 1/1/20)

Fax to PerformRxSM at **1-215-937-5018**, or to speak to a representative call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # pages:	Name/phone of office or LTC facility contact:
PATIENT INFORMATION			
Patient name:		Patient ID#:	DOB:
Street address:		Apt. #:	City/state/zip:
PRESCRIBER INFORMATION			
Prescriber name:		Specialty:	NPI:
Street address:		Suite #:	City/state/zip:
Phone:		Fax:	
CLINICAL INFORMATION			
Drug:			
Strength:	Qty per fill:	to last days	Duration: days / 1 mo /2 mos / 3 mos
Directions:			
Weight (if <21 yrs):	lbs / kg	Diagnosis (submit documentation):	Dx code (required):
1. Did the prescriber or prescriber's delegate search the PDMP to review the patient's controlled substance prescription history before issuing this prescription for the requested agent? <input type="checkbox"/> Yes – <i>Submit documentation.</i> <input type="checkbox"/> No		2. Is the patient taking a benzodiazepine? Submit patient's current medication list. <input type="checkbox"/> Yes – List and provide medical justification: <input type="checkbox"/> No	
3. Initial requests for all NON-PREFERRED medications: Does the patient have a history of trial and failure, contraindication, or intolerance to the preferred short-acting opioids analgesics? Check all that apply.			
<input type="checkbox"/> APAP/codeine tablet or elixir		<input type="checkbox"/> hydrocodone/ibuprofen tablet	<input type="checkbox"/> oxycodone IR tablet
<input type="checkbox"/> Endocet		<input type="checkbox"/> morphine IR tablet	<input type="checkbox"/> oxycodone/APAP tablet
<input type="checkbox"/> hydrocodone/APAP tablet		<input type="checkbox"/> morphine solution or concentrate	<input type="checkbox"/> tramadol IR tablet
<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of trial & failure, contraindications, or intolerances.</i>			
4. What is the anticipated duration of therapy with opioid analgesics? Specify duration: <i>Submit documentation</i>			
5. Is the patient being treated for active cancer, sickle cell with crisis, or neonatal abstinence syndrome OR receiving hospice or palliative care services? <input type="checkbox"/> Yes – Submit documentation. <input type="checkbox"/> No – Continue to the next question.			
6. Check all of the following that apply to the Patient. Submit detailed medical record documentation for EACH item.			
INITIAL requests:			
<input type="checkbox"/> has documentation of a complete physical exam, including diagnostic testing/imaging results, and pain assessment (cause, severity, location, etc)			
<input type="checkbox"/> has tried or cannot try non-drug pain management modalities (eg, behavioral, cognitive, physical, and/or supportive therapies)			
<input type="checkbox"/> has tried or cannot try non-opioid drugs for the treatment of pain – check drugs tried: <input type="checkbox"/> acetaminophen <input type="checkbox"/> NSAIDs <input type="checkbox"/> other: _____			
<input type="checkbox"/> the requested opioid medication will be used in combination with tolerated non-drug therapies and non-opioid medications			
<input type="checkbox"/> was assessed for the potential risk of misuse, abuse, and addiction based on family and social history obtained by prescriber			
<input type="checkbox"/> was counseled regarding potential side effects of opioids including risk of misuse, abuse, addiction (if <21 yo, parent/guardian may be counseled)			
<input type="checkbox"/> was assessed for recent (within the past 60 days) opioid use			
<input type="checkbox"/> was evaluated for risk factors for opioid-related harm			
<input type="checkbox"/> if identified to be at high risk for opioid-related harm, the prescriber considered prescribing naloxone			
<input type="checkbox"/> has a recent UDS testing for illicit and licit substances of abuse (with specific testing for oxycodone, fentanyl, tramadol, and carisoprodol). Date of last UDS: _____			
RENEWAL requests:			
<input type="checkbox"/> experienced an improvement in pain control and level of functioning while on the requested agent			
<input type="checkbox"/> the requested opioid medication will be used in combination with tolerated non-drug therapies and non-opioid medications			
<input type="checkbox"/> is being monitored by the prescriber for adverse events and warning signs of serious problems, such as overdose and opioid use disorder			
<input type="checkbox"/> was evaluated for risk factors for opioid-related harm			
<input type="checkbox"/> if identified to be at high risk for opioid-related harm, the prescriber considered prescribing naloxone			
<input type="checkbox"/> has a recent UDS testing for illicit and licit substances of abuse (with specific testing for oxycodone, fentanyl, tramadol, and carisoprodol). Date of last UDS: _____			
7. For requests for nasal butorphanol (Stadol), check all of the following that apply to the beneficiary. Submit documentation for EACH item.			
<input type="checkbox"/> the patient is opioid-tolerant (names and dosages of current opioid regimen)			
<input type="checkbox"/> if being treated for migraine, has a history of trial & failure of or contraindication or intolerance to abortive (triptans) & preventive medications			

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION	
Prescriber signature:	Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.